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Purpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal 
implant (Ozurdex®; Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis.
Methods: A retrospective chart review of patients with noninfectious uveitis treated with 
  sustained-release dexamethasone 0.7 mg intravitreal implant was performed. Complete 
ophthalmic examination including signs of inflammatory activity, visual acuity, fundus 
  photography, fluorescein angiography, optical coherence tomography, and tolerability of the 
implant were assessed.
Results: Six eyes of 4 consecutive patients treated with a total of 8 dexamethasone 0.7 mg 
sustained-release intravitreal implants for posterior noninfectious uveitis were included. Two 
patients presented with unilateral idiopathic posterior uveitis; 2 patients had bilateral   posterior 
uveitis, one secondary to sarcoidosis and the other to Vogt-Koyanagi-Harada syndrome. 
All eyes showed clinical and angiographic evidence of decreased inflammation following 
implant placement. Mean follow-up time post-injection was 5.25 months. Four eyes received 
1 and 2 eyes received 2 Ozurdex implants during the follow-up period. The duration of effect 
of the implant was 3 to 4 months. No serious ocular or systemic adverse events were noted 
during the follow-up period.
Conclusions: In patients with noninfectious posterior uveitis, sustained-release dexamethasone 
0.7 mg intravitreal implant may be an effective treatment option for controlling intraocular 
inflammation.
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Introduction
The mainstay of treatment for noninfectious uveitis remains corticosteroids. Regional 
steroids have the advantage of minimizing systemic side effects; however, local side 
effects can include increased intraocular pressure, cataract, and sterile and infectious 
endophthalmitis.1,2
Dexamethasone has potent anti-inflammatory properties with a favorable side-effect 
profile.3–5 Previous studies demonstrated that dexamethasone in a biodegradable drug 
delivery system (Ozurdex®; Allergan Inc, Irvine, California, USA) can improve visual 
acuity (BCVA) and macular thickness in a variety of settings.3–5 Here, we describe 
our experience with treating noninfectious posterior uveitis with the Ozurdex 0.7 mg 
dexamethasone intravitreal implant.
Materials and methods
A retrospective chart review of patients treated with Ozurdex for noninfectious posterior 
uveitis was undertaken with IRB approval of Weill Cornell Medical College. Included Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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were demographics, etiology of inflammation, BCVA, prior 
therapies, examination, and adverse events.
Patients underwent a comprehensive examination including 
optical coherence tomography (OCT), fluorescein angiography 
(FA), and fundal photography. A systemic work-up included 
laboratory and radiographic   imaging for   infectious and nonin-
fectious etiologies. Ozurdex was   administered in accordance 
with the manufacturer’s instructions using the 22-gauge 
applicator device (Ozurdex package http://www.allergan.
com/assets/pdf/ozurdex_pi.pdf).
Results
Six eyes of 4 patients were included. Patient demographics, 
diagnosis, and examination findings are summarized 
in Table 1. Mean follow-up time post-injection was 
5.25 months (range 2–8 months). No serious systemic or 
ocular treatment-related adverse events occurred. Sub-
conjunctival hemorrhage occurred at the injection site. 
Intraocular pressures remained unchanged in all eyes during 
follow-up.
Patient 1
A 30-year-old female presented with papillitis and   retinal 
vasculitis of the left eye (OS). A work-up revealed a 
diagnosis of sarcoidosis. Despite 60 mg of oral predni-
sone and 1   sub-Tenon’s triamcinolone injection OS, there 
was persistent inflammation. Similar findings developed 
in the right eye (OD). Ozurdex was administered in both 
eyes (OU). Six months post-Ozurdex and off oral steroids, 
the patient shows no signs of inflammation (Figure 1).
Table 1 Baseline demographics, diagnosis and examination findings of all patients with total follow-up period and final visual acuity 
outcomes
Patient Age Sex Diagnosis Baseline  
BVCA
FA OCT Prior 
treatment
No.  
Ozurdex
Total  
follow-up 
(months)
Final  
BCVA
1 30 F sarcoidosis 20/20 OU Disc and 
perivascular  
leakage
No CMe Prednisone 
60 mg and  
sTT
1 OU 6 OU 20/20 OU
2 49 M Vogt-Koyanagi- 
Harada
Count fingers  
OU
Hyperfluorescent 
dots at level of  
rPe with leakage 
into serous rDs
serous  
rDs
sTT 1 OD  
2 Os
2 OD  
4 Os
20/20 OD 
20/30 Os
3 29 F idiopathic retinal  
vasculitis
Hand motion  
Os
extensive disc, 
perivascular, and  
parafoveal leakage
CMe None 2 8 20/40 Os
4 81 F idiopathic  
anterior NG  
uveitis with CMe
20/50 OD Late parafoveal 
leakage
CMe Topical 
prednisolone 
acetate
1 4 20/50 OD
Abbreviations: BCVA, best-corrected visual acuity snellen equivalent in the study eye; CMe, cystoid macular edema; sTT, sub-Tenon’s triamcinolone; rD, retinal 
detachment; NG, nongranulomatous; OD, right eye; OS, left eye; OU, both eyes; OCT, optical coherence tomography; FA, fluorescein angiography.
Figure  1  A)  Fluorescein  angiography  (FA)  left  eye  (Os)  of  patient  1  showing 
persistent  leakage  of  the  disc  and  perivascular  leakage  (yellow  arrows)  after 
treatment with oral prednisone and sub-Tenon’s triamcinolone Os. B) FA right eye 
(OD) showing progression to the fellow eye with leakage of the disc and perivascular 
leakage (yellow arrow) while on oral prednisone. C–D) FA 4 weeks following the 
0.7 mg dexamethasone implantation in both eyes showing resolution of papillitis 
vasculitis. E) Fundal photography shows the location of the implant in the inferior 
vitreous  base  in  Os.  F–G)  FA  4  months  following  the  0.7  mg  dexamethasone 
intravitreal implant and 6 weeks after finishing oral steroids, showing no recurrence 
of papillitis or vasculitis in both eyes.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Uveitis work-up was unrevealing. BCVA was 20/50. 
Examination showed anterior chamber inflammation. OCT 
showed CME OD. The patient received Ozurdex. At 1-month 
follow-up, off of topical steroids, inflammation and CME 
resolved. BCVA remained 20/50 due to pre-existing cataract. 
Four months post-implant, inflammation and CME returned; 
patient deferred further intervention.
Discussion
In the present series, Ozurdex was able to successfully con-
trol inflammation and improve CME in 4 eyes of 3 patients. 
Two cases failed prior local therapy. The duration of effect 
of the implant was approximately 3 to 4 months. No patients 
developed major systemic or ocular side effects, particularly 
ocular hypertension. However, follow-up time was insuf-
ficient to assess cataract formation.
There was recurrence of SRF after oral prednisone taper 
despite recent Ozurdex implants with probable VKH. There 
have been a few reports of VKH treatment with intravitreal 
corticosteroids with mixed results.7–9 Thus, systemic treat-
ment remains the mainstay of therapy. However, intravitreal 
corticosteroids may play a role as adjuvant therapy.
Although the results of phase 3 trial of Ozurdex in 
  noninfectious uveitis have been completed and Ozurdex 
recently received approval in the United States, this series 
is, to the best of our knowledge, one of first to report clinical 
experience with Ozurdex.10 Our series confirms that Ozurdex 
can be effective for treating noninfectious uveitis; however, 
the durability of that effect was considerably shorter than the 
6-month reinjection interval typically utilized in retinal vein 
Patient 2
A 49-year-old male presented with bullous serous reti-
nal detachments (RD) OU. OCT showed multiple large 
serous RDs. A work-up was positive for HLA-DR4. 
A diagnosis of probable Vogt-Koyanagi-Harada (VKH) 
disease was made.6 The patient received 1 sub-Tenon’s 
triamcinolone injection OS with no improvement. Ozurdex 
was administered OS and oral prednisone 60 mg started. 
BCVA improved to 20/50 OD and 20/25 OS. For persistent 
subretinal fluid (SRF) OD, Ozurdex was given. Both eyes 
developed recurrent SRF after oral prednisone taper. 
A second Ozurdex implant was given OS and oral predni-
sone re-started. At final visit 4 months after initial Ozurdex 
implant, on oral prednisone, BCVA was 20/20 OD and 20/30 
OS with no SRF OU.
Patient 3
A 29-year-old female presented with hand motion 
vision OS. Examination showed vitritis, papillitis, and 
vasculitis OS. OCT showed cystoid macular edema (CME). 
Uveitis work-up was negative; the patient was diagnosed with 
idiopathic ocular inflammtion. Ozurdex was administered. 
At 2.5 months post-Ozurdex, BCVA was 20/40 without 
CME. At 4-month follow-up, OCT showed recurrent CME. 
A second Ozurdex was given. Four months after the second 
implant, BCVA was 20/40 with no CME (Figure 2).
Patient 4
An 81-year-old female presented with recurrent nongranu-
lomatous uveitis OD treated with topical prednisolone. 
Figure 2 A) Baseline fundal photography left eye (Os) of patient 3 showing vitritis, papillitis and widespread vasculitis with extensive sheathing of the vessels in Os. 
B) Baseline fluorescein angiography (FA) right eye (OD) showing no evidence of inflammation. C) Baseline FA Os revealed papillitis and considerable vasculitis Os. D) 
Baseline optical coherence tomography (OCT) Os with cystoids macular edema (CMe). E) FA Os 11 days following the 0.7 mg dexamethasone intravitreal implant showed 
significantly decreased perivascular, optic disc, and parafoveal leakage, and F) OCT revealed a drastic reduction in CMe. G) 2.5 months following implant placement OCT Os 
showed no recurrence of CMe. H) Almost 4 months following implant placement OCT Os showed return of CMe. I) Two months after receiving a second dexamethasone 
implant OCT Os showed resolution of CMe.Clinical Ophthalmology
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occlusion.11 Further prospective, controlled studies need to 
be performed to better determine efficacy, duration of effect, 
and side effects.
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